{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-054999","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2023-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.349959+00:00","generated_at":"2026-06-09T10:29:31.204612+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Alkermes Q3 2023 revenue $380.9M, GAAP net income $47.8M; reiterates FY guidance; oncology split in Nov","bullets":["Total Q3 revenues $380.9M vs $252.4M YoY; proprietary product sales up 16% to $231.8M.","GAAP net income $47.8M ($0.28 diluted EPS) vs GAAP net loss of $64.0M YoY; non-GAAP net income $109.5M ($0.64 diluted EPS).","LYBALVI net sales $50.7M (+87% YoY); VIVITROL $99.3M (+3%); ARISTADA $81.8M (+8%).","Cash & investments $995.6M; debt $291.4M; reiterates FY2023 guidance.","Expects oncology spin-off (Mural) Nov 2023 with $275M; settled VIVITROL patent suit with Teva (generic Jan 2027)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-054999","json":"https://secwatch.observer/filing/0000950170-23-054999.json","markdown":"https://secwatch.observer/filing/0000950170-23-054999.md","text":"https://secwatch.observer/filing/0000950170-23-054999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000095017023054999/0000950170-23-054999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000095017023054999/alks-20231025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T10:29:31.204612+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"696f067f6e7f2d2f6f8c30ac400d27ff0589dda2","claim":"Alkermes plc. updated its three and nine months ended September 30, 2023 guidance (reaffirmed).","evidence_excerpt":"On October 25, 2023, Alkermes plc (the “Company”) announced financial results for the three and nine months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1520262/000095017023054999/0000950170-23-054999-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}